Patents by Inventor Guillermo BARRETO

Guillermo BARRETO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOFORMS OF GATA6 AND NKX2-1 AS MARKERS FOR DIAGNOSIS AND THERAPY OF CANCER AND AS TARGETS FOR ANTI-CANCER THERAPY
    Publication number: 20220195529
    Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.
    Type: Application
    Filed: July 27, 2021
    Publication date: June 23, 2022
    Inventors: Guillermo BARRETO, Aditi MEHTA, Indrabahadur SINGH, Marten SZIBOR, Rajkumar SAVAI, Werner SEEGER, Thomas BRAUN, Andreas GÜNTHER, Marcus KRÜGER
  • ISOFORMS OF GATA6 AND NKX2-1 AS MARKERS FOR DIAGNOSIS AND THERAPY OF CANCER AND AS TARGETS FOR ANTI-CANCER THERAPY
    Publication number: 20200181717
    Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.
    Type: Application
    Filed: October 23, 2019
    Publication date: June 11, 2020
    Inventors: Guillermo BARRETO, Aditi MEHTA, Indrabahadur SINGH, Marten SZIBOR, Rajkumar SAVAI, Werner SEEGER, Thomas BRAUN, Andreas GÜNTHER, Marcus KRÜGER
  • Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
    Patent number: 10501803
    Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: December 10, 2019
    Assignees: MAX-PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN
    Inventors: Guillermo Barreto, Aditi Mehta, Indrabahadur Singh, Marten Szibor, Rajkumar Savai, Werner Seeger, Thomas Braun, Andreas Günther, Marcus Krüger
  • EMBRYONIC ISOFORMS OF GATA6 AND NKX2-1 FOR USE IN LUNG CANCER DIAGNOSIS
    Publication number: 20180051344
    Abstract: The present invention relates to a Statistical method of assessing whether a subject suffers from Cancer or is prone to suffering from Cancer, said method comprising the step of performing at least one Statistical algorithm for Classification and for regression on measurement data of the subject, wherein the measurement data of the subject comprises at least one of the following: a value of GATA6 Em isoform in at least one sample taken from the subject, a value NKX2-1 Em isoform in said at least one sample, a value of GATA6 Ad isoform in said at least one sample, NKX2-1 Ad isoform in said at least one sample; and wherein at least one of the following is used as at least one classifier or a component of at least one classifier in the Statistical method: GATA6 Em isoform, NKX2-1 Em isoform, GATA6 Ad isoform, NKX2-1 Ad isoform, ratio of GATA6 Em isoform/GATA6 Ad isoform, ratio of NKX2-1 Em isoform/NKX2-1 Ad isoform.
    Type: Application
    Filed: November 3, 2015
    Publication date: February 22, 2018
    Inventors: Guillermo BARRETO, Aditi MEHTA, Achim TRESCH, Stephanie DOBERSCH, Addi Josua ROMERO OLMEDO, Werner SEEGER, Thomas BRAUN, Andreas GÜNTHER
  • ISOFORMS OF GATA6 AND NKX2-1 AS MARKERS FOR DIAGNOSIS AND THERAPY OF CANCER AND AS TARGETS FOR ANTI-CANCER THERAPY
    Publication number: 20160244842
    Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.
    Type: Application
    Filed: May 21, 2014
    Publication date: August 25, 2016
    Inventors: Guillermo BARRETO, Aditi MEHTA, Indrabahadur SINGH, Marten SZIBOR, Rajkumar SAVAI, Werner SEEGER, Thomas BRAUN, Andreas GÜNTHER, Marcus KRÜGER